EAM
ASND icon

Exome Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Exome Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,849
Closed -$6.55M – 65
2024
Q3 		$6.55M Buy
43,849
+23,849
+119% +$3.22M 4.43% 2
2024
Q2 		$2.73M Buy
+20,000
New +$2.72M 2.43% 17

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Exome Asset Management's ASND Position: Q4 2024 in Review

Exome Asset Management sold out of Ascendis Pharma A/S (ASND) in Q4 2024, closing a stake of 43,849 shares — an estimated $6.55M sold.

Exome Asset Management first reported a position in ASND in Q2 2024 and held it in 2 quarters. The position peaked at $6.55M in Q3 2024. 214 funds tracked by Wall St. Rank hold ASND as of Q4 2024.

  • Exome Asset Management reported no remaining Ascendis Pharma A/S position as of Q4 2024 after selling out during the quarter.
  • Exome Asset Management sold 43,849 Ascendis Pharma A/S shares in Q4 2024, an estimated $6.55M.
  • Exome Asset Management first reported a position in Ascendis Pharma A/S in Q2 2024 and held it in 2 quarters.
  • Exome Asset Management's Ascendis Pharma A/S position peaked at $6.55M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2024.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.